nivolumab is a standard option for second-line treatment in pts with advanced NSCLC. However, data regarding the efficacy of nivolumab as well as post-nivolumab treatment in large cohorts of patients treated in real-life settings, are lacking.

**Objectives**

- Overall survival (OS)
- Best response, progression-free survival (PFS) to nivolumab
- Best response, progression-free survival (PFS) to post-nivolumab treatment (R)
- Predictors of response and survival to nivolumab and post first-treatment
- Toxicity of nivolumab

**Methods**

This analysis included 902 pts with stage IIIb/IV NSCLC who initiated 21 dose of nivolumab 3mg/kg trough the French EAP from 01/2015 to Squamous (Squ) and 06/2015 for Non-Squamous (NsQ), until 06/2018. Data were collected from medical records at each study site.

**Study flowchart**

- n=657 pts included in the 1st-line nivolumab study
- n=26 pts included in the current analysis (n=379 [35%] NsQ; 65% [63%] Squ)

**Nivolumab discontinuation (n=815)**

- Progression (n=887; 72.6%)
- Death (n=77; 5.8%)
- Toxicity (n=73; 6.0%)
- Investigator's decision (n=56; 5.1%)
- Left the clinic (n=51; 1.7%)
- Intercurrent disease (n=50; 1.7%)
- Patient refused (n=20; 0.7%)
- Other (n=11; 0.1%)

Ongoing nivolumab

n=26 post-nivolumab treatment
g=639 post-first treatment systems

**Drug summary**

- Median follow up: 26.1 months; 95% CI [25.8-27.4]
- Median duration 2 months [Mon, Max 25.5]

**Baseline characteristics**

<table>
<thead>
<tr>
<th>Sex</th>
<th>F</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>290</td>
<td>64.8</td>
</tr>
<tr>
<td>Female</td>
<td>157</td>
<td>35.2</td>
</tr>
</tbody>
</table>

**Efficacy of nivolumab**

Best response to nivolumab

- Overall response (OR) = 28.0% (95% CI 23.0-33.2)
- Complete response (CR) = 8.8% (95% CI 6.0-12.6)
- Partial response (PR) = 20.2% (95% CI 15.7-25.7)
- Stable disease (SD) = 35.1% (95% CI 28.3-42.3)
- Progressive disease (PD) = 21.3% (95% CI 16.9-26.4)

**Efficacy of post-nivolumab treatment**

Best response to first post-nivolumab systemic treatment (n=319): OR=1.6-2.3; SD=34-51.3; PD=41.5%.

**Prognostic factors of OS**

- Male gender
- Age at initiation of nivolumab, smoking history, TNM stage, histology were not associated with OS.

**Access to post-nivolumab treatment**

815 (90%) of patients had discontinued nivolumab. Post-nivolumab treatment was administered to 426 (46%) patients. Patients with a PS01, 1 or 2 prior lines and patients with PD (including nivolumab initiation) were more common in the population with post-nivolumab treatment. Ongoing treatment: n=102 (76.2%)

**Conclusions**

Efficacy and safety of nivolumab was in line with data from clinical trials. Post-nivolumab treatment may be delivered in many patients, with high variable efficacy and impact on OS.

**References**

*Corresponding author: nicolas.girard2@curie.fr

**Study funded by:** IFCF

**Funding sources:** BMS, IFCT, French League Against Cancer

**www.ifct.fr**

**1302PO - ESOM 2017**

**N. Girard** 1,2, C. Audigier Valette 2, J. Cad squadron 1, I. Monnet 1, J. Hureaux 1, W. Higlitzer 2, E. Fauchon 2, E. Fabre 2, B. Besse 2, P. Brun 2, D. Cobi 2, E. Quichot 2, P. Touret 2, F. Barlesi 2, S. Bourdaine-Caffre 2, T. Egenolf 2, P. Missony 3, F. Monrie 4, M. Grob-Siblot 2, O. Molinier 2

1 Thomas Institute Curie-umontiers, Institut Curie, Paris, FR, 2 Rheumatology, Centre Hospitalier Toulon Sainte-Marie, Toulon, FR, 3 Rheumatology, APHP, Tenon University Hospital, Paris, FR, 4 Medical Oncology, Centre Hospitalier Toulon Sainte Marie, Toulon, FR, 5 Medical Oncology, Centre Hospitalier Toulon Sainte Marie, Toulon, FR, 6 Medical Oncology, CHU de Saint Brieuc, Saint Brieuc, FR, 7 Medical Oncology, Centre Hospitalier Toulon Sainte-Marie, Toulon, FR, 8 Medical Oncology, Multidisciplinary Oncology & Therapeutic Innovations, Aix Marseille University, Marseille, FR, 9 Medical Oncology, Pole Hippocrate, CHU Angers, Angers, FR, 10 Medical and Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), Paris, FR, 11 Medical Oncology, CHU Limoges, Limoges, FR, 12 Medical Oncology, Centre Hospitalier Toulon Sainte Marie, Toulon, FR, 13 Medical Oncology, CHU Angers, Angers, FR, 14 Medical Oncology, Centre Hospitalier Toulon Sainte Marie, Toulon, FR, 15 Medical Oncology, CHU de Saint Brieuc, Saint Brieuc, FR.